<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tufted angioma, kaposiform hemangioendothelioma (KHE), and Kasabach-Merritt phenomenon (KMP)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tufted angioma, kaposiform hemangioendothelioma (KHE), and Kasabach-Merritt phenomenon (KMP)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tufted angioma, kaposiform hemangioendothelioma (KHE), and Kasabach-Merritt phenomenon (KMP)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denise M Adams, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ilona J Frieden, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H357895344"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tufted angioma and kaposiform hemangioendothelioma (KHE) are rare, vascular tumors that typically occur during infancy or early childhood. Tufted angioma, previously known as "angioblastoma of Nakagawa," is a benign tumor; the name derives from its histopathologic appearance, characterized by tufts of capillaries within the dermis [<a href="#rid1">1,2</a>]. KHE is a locally aggressive tumor that may involve superficial and deep soft tissues and, rarely, the retroperitoneum, mediastinum, and internal organs [<a href="#rid3">3,4</a>].</p><p>Tufted angioma and KHE share several histopathologic and clinical features and are thought to be part of the same neoplastic spectrum [<a href="#rid5">5,6</a>]. The most serious complication of these tumors is Kasabach-Merritt phenomenon (KMP), a life-threatening coagulopathy characterized by severe thrombocytopenia and consumption of fibrinogen and other coagulation factors [<a href="#rid7">7</a>].</p><p>Tufted angioma, KHE, and KMP will be discussed in this topic. Infantile hemangiomas, congenital hemangiomas, venous malformations, capillary malformations and associated syndromes, and Klippel-Trenaunay syndrome are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infantile hemangiomas</strong> – (See  <a class="medical medical_review" href="/z/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications"</a> and  <a class="medical medical_review" href="/z/d/html/5793.html" rel="external">"Infantile hemangiomas: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5792.html" rel="external">"Infantile hemangiomas: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital hemangiomas</strong> – (See  <a class="medical medical_review" href="/z/d/html/13727.html" rel="external">"Congenital hemangiomas: Rapidly involuting congenital hemangioma (RICH), noninvoluting congenital hemangioma (NICH), and partially involuting congenital hemangioma (PICH)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular malformations</strong> – (See  <a class="medical medical_review" href="/z/d/html/110155.html" rel="external">"Venous malformations"</a> and  <a class="medical medical_review" href="/z/d/html/13726.html" rel="external">"Capillary malformations (port wine birthmarks) and associated syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/13730.html" rel="external">"Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="headingAnchor" id="H357895351"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Tufted angioma and KHE are rare [<a href="#rid8">8,9</a>]. Their exact incidence is unknown. Based upon the cases observed at a large referral center, the incidence of KHE has been estimated at 0.07/100,000 children per year [<a href="#rid3">3</a>].</p><p>Males and females are affected equally. Approximately 50 percent of cases are present at birth; the remainder develop after the neonatal period, most often in the first year of life. However, later onset during childhood and even in adulthood has been reported [<a href="#rid10">10</a>]. KMP occurs in approximately 70 percent of cases of KHE and 10 percent of tufted angiomas [<a href="#rid3">3,11</a>].</p><p class="headingAnchor" id="H357895358"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of tufted angioma and KHE is poorly understood. The neoplastic spindle cells of KHE express the vascular markers CD31 and CD34, the vascular endothelial growth factor receptor 3 (VEGFR-3), a receptor required for lymphangiogenesis, and the lymphatic markers D2-40 and PROX1 [<a href="#rid4">4,5,12-14</a>]. These findings suggest that KHE may derive from the lymphatic endothelium, similarly to Kaposi sarcoma. However, in contrast with Kaposi sarcoma, human herpesvirus 8 (HHV-8) transcripts have not been identified in KHE, and there is no evidence of association with HHV-8 infection [<a href="#rid12">12</a>]. Data regarding genomic alterations in these tumors are limited, but there have been a few reports of mutations in <em>GNA14</em> in some (but not all) cases [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H357895365"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H357895374"><span class="h2">Tufted angioma</span><span class="headingEndMark"> — </span>Tufted angiomas usually present as infiltrated, firm, dusky red to violaceous plaques or nodules with ill-defined borders (<a class="graphic graphic_picture graphicRef89065" href="/z/d/graphic/89065.html" rel="external">picture 1E</a>). The size varies from less than 1 cm to more than 10 cm. Lesions are typically located on the arms, legs, and trunk [<a href="#rid16">16</a>]. In contrast with infantile hemangiomas, craniofacial lesions are uncommon. Lanugo hair hypertrichosis and increased sweating in the area overlying the tumor also have been described [<a href="#rid17">17</a>].</p><p>Tufted angioma typically manifests during infancy or early childhood, but cases with onset in adult life have been reported [<a href="#rid10">10,18,19</a>]. At birth, lesions are either absent or barely evident as a faint pink or brown discoloration. Over time, the tumor thickens into a plaque, often becoming dusky red or violaceous in color (<a class="graphic graphic_picture graphicRef89065" href="/z/d/graphic/89065.html" rel="external">picture 1E</a>). Some develop distinct nodularity or focal papules. Eventually, lesions stabilize in size and tend to persist unchanged. However, partial or complete regression during infancy or childhood has been reported in a few cases [<a href="#rid20">20,21</a>].</p><p>Tufted angiomas are usually solitary, but multifocal or disseminated disease has been reported [<a href="#rid22">22</a>]. A rare, eruptive form has been described in immunosuppressed patients [<a href="#rid23">23</a>]. Approximately 10 percent of tufted angiomas develop KMP [<a href="#rid11">11</a>]. (See <a class="local">'Kasabach-Merritt phenomenon'</a> below.)</p><p class="headingAnchor" id="H357895381"><span class="h2">Kaposiform hemangioendothelioma</span><span class="headingEndMark"> — </span>KHE<strong> </strong>appears as a slightly raised, expanding, subcutaneous mass with a purpuric, bruised appearance and occasional telangiectasias (<a class="graphic graphic_picture graphicRef89343 graphicRef89260" href="/z/d/graphic/89343.html" rel="external">picture 1A-B</a>) [<a href="#rid7">7,24,25</a>]. Increased hair growth or sweating overlying the tumor may be evident. In some cases, the appearance of these lesions can be dramatic, with massive involvement of an entire extremity or other body parts. As the tumor grows, it infiltrates surrounding tissue planes (<a class="graphic graphic_picture graphicRef89264" href="/z/d/graphic/89264.html" rel="external">picture 1D</a>).</p><p>KHE may be present at birth or develop in early childhood. Over time, especially in cases associated with severe coagulopathy, the tumor becomes indurated and firm, with a red-purple hue, ecchymoses, and petechiae (<a class="graphic graphic_picture graphicRef89100 graphicRef89343" href="/z/d/graphic/89100.html" rel="external">picture 1A, 1C</a>).</p><p>In most cases, the tumor involves the extremities, resulting in musculoskeletal dysfunction with decreased range of motion or pain. Less frequent locations include the trunk and the cervicofacial region [<a href="#rid3">3</a>]. Approximately 10 percent of KHEs do not involve the skin. The retroperitoneum is the most frequent extracutaneous location, followed by muscle, bone, and thoracic cavity. Deep retroperitoneal lesions or intrathoracic lesions can cause a bluish, purpuric hue on the skin and may be mistaken for a bleeding disorder. KHE with osseous extension can occur and may uncommonly present with the bone as the primary site of involvement [<a href="#rid26">26</a>].</p><p>Over 70 percent of KHEs develop KMP [<a href="#rid3">3</a>]. The risk is highest for large, congenital lesions and lesions located in the retroperitoneum or mediastinum. (See <a class="local">'Kasabach-Merritt phenomenon'</a> below.)</p><p>Tumors without KMP usually occur in toddlers or older children and are relatively small (&lt;8 cm in diameter) [<a href="#rid27">27</a>]. They appear as firm soft tissue masses that can be indurated, light brown, violaceous, or erythematous in color, without purpura or petechiae. These tumors can cause pain or functional impairment depending on the area of involvement [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H357895395"><span class="h2">Kasabach-Merritt phenomenon</span><span class="headingEndMark"> — </span>KMP is a life-threatening complication occurring in approximately 70 percent of cases of KHE and 10 percent of tufted angiomas [<a href="#rid3">3,11</a>]. KMP is characterized by profound thrombocytopenia and consumption coagulopathy.</p><p>Since its first description in an infant with a "giant capillary hemangioma," the term has been used indiscriminately to describe thrombocytopenia or coagulopathy associated with any vascular anomaly [<a href="#rid7">7</a>]. However, it is now clear that KMP is a complication of tufted angioma and KHE and not of infantile or congenital hemangiomas [<a href="#rid7">7,25</a>]. These tumors can cause pain or functional impairment depending on the area of involvement [<a href="#rid24">24</a>].</p><p>Why KMP develops exclusively in the setting of tufted angioma or KHE is unclear. One hypothesis is that the abnormal endothelium and convoluted architecture of the tumor vasculature promote platelet trapping, activation, and consumption [<a href="#rid29">29</a>]. Platelet aggregation and activation result in thrombocytopenia, consumption of fibrinogen, and ongoing fibrinolysis, leading to intralesional bleeding and tumor enlargement [<a href="#rid8">8</a>].</p><p>The presenting sign of KMP is a rapid enlargement of the tumor, which becomes tense, purpuric or ecchymotic, and painful (<a class="graphic graphic_picture graphicRef89100 graphicRef89264" href="/z/d/graphic/89100.html" rel="external">picture 1C-D</a>). These changes are accompanied by a rapid drop in the platelet count. The typical platelet count ranges from 3000 to 60,000/microL. Fibrinogen levels are usually &lt;100 mg/dL; D-dimer and fibrin degradation products are elevated. The prothrombin time (PT) and the activated partial thromboplastin time (aPTT) are usually normal or minimally elevated.</p><p>Severe anemia caused by sequestration of red blood cells in the tumor may also occur. Occasionally, schistocytes (evidence of a microangiopathic hemolytic anemia) can be seen on the blood smear. (See  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)", section on 'Microangiopathic hemolytic anemia (MAHA)'</a>.)</p><p>Despite the profound thrombocytopenia, severe hemorrhage is rare. However, trauma (eg, biopsy, surgical procedure), ulceration, infection, or delay in initiating treatment may induce progression to a more systemic coagulopathy similar to disseminated intravascular coagulation [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children"</a>.)</p><p class="headingAnchor" id="H357895402"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of tufted angioma and KHE is based upon the combination of clinical, histologic, and imaging features. Laboratory evaluation is essential for the diagnosis of KMP.</p><p class="headingAnchor" id="H26920701"><span class="h2">Clinical examination</span><span class="headingEndMark"> — </span>The diagnosis of tufted angioma or KHE is suspected in an infant presenting with an atypical, indurated, vascular lesion, red to purple in color with ill-defined borders, most often located on the extremities or trunk (<a class="graphic graphic_picture graphicRef89065 graphicRef89100 graphicRef89264 graphicRef89343" href="/z/d/graphic/89065.html" rel="external">picture 1A, 1C-E</a>). The presence of hypertrichosis and/or hyperhidrosis overlying the lesion is a clue to the diagnosis. (See <a class="local">'Tufted angioma'</a> above and <a class="local">'Kaposiform hemangioendothelioma'</a> above.)</p><p class="headingAnchor" id="H3945555892"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) is important in differentiating tufted angioma and KHE from other tumors, in delineating the extent of the disease, and in documenting the response to treatment, particularly in cases with extracutaneous involvement [<a href="#rid30">30-33</a>]. T1-weighted sequences typically show a poorly circumscribed soft tissue mass with multiplanar involvement and diffuse enhancement with gadolinium. T2-weighted sequences show a diffuse, increased signal with stranding in the subcutaneous fat. Gradient sequences show mildly dilated vessels in and around the soft tissue mass. MRI can also show involvement or destruction of the adjacent bone.</p><p>Ultrasonography is used for small and superficial tumors. On ultrasonography, KHE appears as an ill-defined, focal or diffuse lesion confined to subcutaneous fat or infiltrating the subcutaneous tissue and underlying muscle. Color doppler scan shows increased vascularity with high velocity flow [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H4216140392"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>Laboratory evaluation of tufted angioma and KHE includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with platelet count</p><p class="bulletIndent1"><span class="glyph">●</span>Fibrinogen</p><p class="bulletIndent1"><span class="glyph">●</span>D-dimer</p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin time (PT)</p><p class="bulletIndent1"><span class="glyph">●</span>Activated partial thromboplastin time (aPTT)</p><p class="bulletIndent1"><span class="glyph">●</span>International normalized ratio (INR)</p><p></p><p>A comprehensive metabolic panel including liver and kidney function tests should be performed in acutely ill patients.</p><p>The detection of severe thrombocytopenia, hypofibrinogenemia, and elevated D-dimer suggests the diagnosis of KMP. However, other rare tumors of infancy (eg, congenital hemangiomas, hemangiopericytoma, infantile fibrosarcoma, angiosarcoma) and venous malformations may be associated with thrombocytopenia and coagulopathy. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H26920734"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>Whenever possible, histologic confirmation of the diagnosis of tufted angioma or KHE should be considered, since therapy is often needed for a prolonged period of time. However, the presence of a highly vascular tumor together with thrombocytopenia and coagulopathy, although not an absolute contraindication for biopsy, greatly increases the risk of bleeding from a biopsy.</p><p>If clinical and imaging findings are highly suggestive of the diagnosis, deferring biopsy is an option. If a biopsy is deemed necessary in a patient with severe coagulopathy, relevant specialists (ie, hematologist, surgeon, anesthesiologist) should be involved in careful planning to minimize complications, and the biopsy should be performed in the operating room or interventional radiology suite. Supportive care with platelet transfusions, cryoprecipitate, and other products may be needed pre- and postoperatively and during the procedure.</p><p class="headingAnchor" id="H3653152187"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>The diagnosis of tufted angioma is confirmed by the finding of multiple discrete lobules of tightly packed capillaries (tufts) scattered in the dermis and sometimes in the subcutis in a so-called "cannonball" pattern (<a class="graphic graphic_picture graphicRef89833" href="/z/d/graphic/89833.html" rel="external">picture 2</a>) [<a href="#rid35">35</a>]. These capillary tufts are surrounded by cleft-like, semilunar, empty, vascular spaces. Thin-walled, lymphatic spaces may be seen throughout the dermis. Mitoses are rare.</p><p>The finding of dilated, thin-walled vessels surrounded by coalescing lobules or sheets of tightly packed, spindled or more rounded endothelial cells, with an infiltrative pattern in the dermis, subcutaneous fat, and muscles, is diagnostic of KHE (<a class="graphic graphic_picture graphicRef89834" href="/z/d/graphic/89834.html" rel="external">picture 3</a>). Slit-like lumina reminiscent of Kaposi sarcoma may be seen. Mixed with these areas are nests of rounded epithelioid cells of vascular origin and aggregates of capillaries with round or irregularly shaped lumens containing platelet-rich fibrin thrombi. There is usually the presence of abnormal, lymphatic spaces either within or at the periphery of the lesion. The rate of mitosis is variable but usually low.</p><p>Immunohistochemical studies reveal that the endothelial cells express the vascular markers CD31 and CD34 and the vascular endothelial growth factor receptor 3 (VEGFR-3), a marker of lymphangiogenesis, in both tufted angioma and KHE. The lymphatic markers D2-40 and PROX1 are also positive, supporting the concept of "lymphothelial" tumors arising from the lymphatic endothelium [<a href="#rid4">4,5,12,13</a>]. Of note, GLUT1, the marker for infantile hemangiomas, is always negative.</p><p>The significant morphologic overlap between tufted angioma and KHE suggests that they may be part of a continuum, in which superficial, cutaneous lesions show the classical findings of tufted angioma and lesions infiltrating the subcutaneous tissues or involving visceral sites have the features of KHE [<a href="#rid6">6,36,37</a>].</p><p class="headingAnchor" id="H357895423"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of tufted angioma and KHE includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infantile hemangiomas</strong> – Infantile hemangiomas are not completely formed at birth, are more commonly located in the head and neck area, and have a predilection for females (<a class="graphic graphic_picture graphicRef60004 graphicRef50388" href="/z/d/graphic/60004.html" rel="external">picture 4A-B</a>). They are <strong>not</strong> associated with a coagulopathy. On histology, they exhibit lobulated masses of proliferating endothelial cells and strong expression of GLUT1. (See  <a class="medical medical_review" href="/z/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital hemangiomas</strong> – Congenital hemangiomas are vascular tumors that are fully formed at birth (<a class="graphic graphic_picture graphicRef88803 graphicRef88800" href="/z/d/graphic/88803.html" rel="external">picture 5A-B</a>). Rapidly involuting congenital hemangioma (RICH) can cause platelet trapping with mild thrombocytopenia and hypofibrinogenemia, which resolve spontaneously over a few weeks. Clinically, RICH can be quite difficult to distinguish from those KHEs that present as tumors at birth. Histologically, RICH differs in having lobules of capillary proliferations embedded in a fibrous stroma without spindle cell or lymphatic ectasias. (See  <a class="medical medical_review" href="/z/d/html/13727.html" rel="external">"Congenital hemangiomas: Rapidly involuting congenital hemangioma (RICH), noninvoluting congenital hemangioma (NICH), and partially involuting congenital hemangioma (PICH)"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kaposiform lymphangiomatosis </strong>– Kaposiform lymphangiomatosis (KLA) is a new entity classified under the heading of lymphatic anomaly that is distinct from generalized lymphatic anomaly and KHE in its histology, clinical course, and outcome [<a href="#rid38">38,39</a>]. Histologically, KLA is characterized by diffuse, lymphatic malformation with focal areas of "kaposiform" spindle cells versus the diffuse nature of the spindle cells in KHE. Somatic activating variants in <em>NRAS</em> have been found in KLA specimens [<a href="#rid40">40</a>]. Clinically, KLA can be multifocal or diffuse throughout the lung and/or abdomen. Other organ involvement can occur, including soft tissue, bone, spleen, liver, and brain. The disorder is associated with hemorrhagic pleural effusions and/or ascites. Patients can have mild to severe coagulopathy similar to KHE, including thrombocytopenia and hypofibrinogenemia. <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">Vincristine</a>, steroids, and <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> have all been used for treatment; however, the mortality is high despite aggressive therapy [<a href="#rid38">38,41-43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infantile myofibromatosis</strong> – Formerly known as infantile hemangiopericytoma [<a href="#rid44">44-46</a>], infantile myofibromatosis is a rare soft tissue tumor that can contain two different clinical entities, the adult type and the infantile type, with the latter occurring in the first year of life [<a href="#rid47">47</a>]. In newborns and infants, the tumor may present as a multilobulated mass in the subcutis (<a class="graphic graphic_picture graphicRef89197" href="/z/d/graphic/89197.html" rel="external">picture 6</a>). Consumption coagulopathy and bleeding may occur and mimic KMP. Histology reveals well-circumscribed nodules of round-shaped and spindle-shaped cells with variable cytologic atypia and haphazard, perivascular orientation and an increased number of thin-walled, branching "staghorn" vessels. (See  <a class="medical medical_review" href="/z/d/html/5788.html" rel="external">"Skin nodules in newborns and infants", section on 'Infantile myofibromatosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infantile fibrosarcoma</strong> – Infantile fibrosarcoma is a rare, malignant tumor that can be present at birth or develop in the first years of life. Lesions present as rounded, firm tumors fixed to the deep tissue planes [<a href="#rid48">48</a>]. Congenital lesions may mimic KHE, particularly when associated with thrombocytopenia and coagulopathy. Histology is required for a precise diagnosis. (See  <a class="medical medical_review" href="/z/d/html/5788.html" rel="external">"Skin nodules in newborns and infants", section on 'Infantile fibrosarcoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venous malformations</strong> – Venous malformations are slow-flow vascular malformations that usually present at birth as soft, compressible, blue masses that enlarge when the affected area is in a dependent position or with physical activity or crying. Venous malformations can be multifocal or diffuse. Imaging studies, including Doppler ultrasonography and MRI, are helpful in distinguishing venous malformations from vascular tumors [<a href="#rid49">49</a>]. In extensive venous malformations (multifocal or diffuse), localized intravascular clotting results in consumption coagulopathy, with elevated D-dimers and low fibrinogen. However, in contrast with KMP, thrombocytopenia is mild, with platelet counts rarely lower than 50,000 to 60,000/microL. (See  <a class="medical medical_review" href="/z/d/html/110155.html" rel="external">"Venous malformations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiosarcomas</strong> –<strong> </strong>Angiosarcomas are extremely rare in children, but cases have been reported in neonates and toddlers, with presentation of multiple cutaneous lesions and liver lesions, some of which are <em>GLUT1</em> positive [<a href="#rid17">17,18,36,37,50</a>]. Large lesions and multiple lesions have been associated with coagulopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kaposi sarcoma </strong>– Kaposi sarcoma is exceedingly rare in children born outside of Africa. Histologically, Kaposi sarcoma presents with extensive, vascular proliferation in the dermis with multiple dilated, vascular spaces and solid cords and fascicles of spindle cells arranged between the jagged, vascular channels. The viral genome of human herpesvirus 8 (HHV-8) is detectable in Kaposi sarcoma lesions at all stages, regardless of the clinical variant [<a href="#rid51">51,52</a>]. Coagulopathy is not common in these lesions. (See  <a class="medical medical_review" href="/z/d/html/7729.html" rel="external">"Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/z/d/html/8033.html" rel="external">"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H357895430"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The approach to the treatment of tufted angioma and KHE must be individualized, based upon the size, location, presence of symptoms (eg, tenderness or functional compromise), and presence or absence of thrombocytopenia and coagulopathy (KMP).</p><p>Guidelines for the management of complicated KHE were proposed in 2013 by an American and Canadian multidisciplinary expert panel, based upon a review of the available evidence, expert opinion, and clinical experience [<a href="#rid53">53</a>]. At the time, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> was just beginning to emerge as a treatment for vascular anomalies. Its role as a therapy for KHE and KMP has been subsequently emphasized. (See <a class="local">'Sirolimus plus systemic corticosteroids'</a> below.)</p><p class="headingAnchor" id="H55701629"><span class="h2">Patients without Kasabach-Merritt phenomenon</span><span class="headingEndMark"> — </span>Several forms of treatment have been proposed for tufted angioma and KHE that are not complicated by KMP. They include surgical excision, pulsed dye laser (for superficial, stain-like tumors), topical agents (eg, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>), systemic agents including corticosteroids, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, and sirolimus. The efficacy of these various treatment modalities has not been evaluated in randomized trials or large observational studies. Limited evidence is based upon small case series, single case reports, and clinical experience.</p><p class="headingAnchor" id="H22141999"><span class="h3">Asymptomatic tumors without Kasabach-Merritt phenomenon</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Observation</strong> – For tumors of any size that are asymptomatic, do not involve vital organs, do not cause functional compromise, and are not disfiguring, observation may be an option. Spontaneous regression of tufted angioma during infancy or early childhood has been reported in a few patients [<a href="#rid20">20,54-56</a>]. In a series of five patients with KHE without KMP who did not receive any treatment, two tumors regressed spontaneously within two years, and three tumors remained stable after a follow-up time of 15 months to 6.5 years [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical excision</strong> – Surgical excision, if feasible, is the treatment of choice for patients who desire definitive treatment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical therapies</strong> – <a class="drug drug_general" data-topicid="138308" href="/z/d/drug information/138308.html" rel="external">Topical sirolimus</a> and topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> have been reported as beneficial in a limited number of cases, but their place as therapeutic agents for superficial KHE or tufted angioma is uncertain. In two small case series, topical sirolimus was reported to be effective in causing fading and improvement of local symptoms of tufted angiomas [<a href="#rid57">57,58</a>]. Topical sirolimus 0.2% gel is available by prescription in the United States; however, prior reports used higher concentrations compounded for topical use.</p><p></p><p class="bulletIndent1">Topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1%, commonly used as a steroid-sparing treatment for atopic dermatitis, has also been reported to be effective in treating superficial KHE and tufted angioma in a small case series (six patients) and in a case report [<a href="#rid59">59,60</a>]. The mechanisms for its benefits may include local anti-inflammatory effects as well as inhibition of local angiogenic factors.</p><p></p><p class="headingAnchor" id="H868181289"><span class="h3">Symptomatic tumors without Kasabach-Merritt phenomenon</span><span class="headingEndMark"> — </span>For patients with tumors that are relatively well localized but are causing symptoms, disfigurement, or functional compromise, surgical excision, if feasible, is the preferred treatment [<a href="#rid17">17,56</a>]. However, since the tumor margins are often poorly defined, complete surgical excision may not be possible, and medical therapy is needed.</p><p>There is no consensus on the pharmacologic treatment of nonresectable tumors that have a high risk of functional compromise. Our approach would be to start medical therapy prior to surgery:</p><p class="bulletIndent1"><span class="glyph">●</span>For tufted angioma, we suggest <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 5 mg/kg per day as first-line therapy [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For KHE, in accord with an expert consensus panel, we suggest oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> 2 mg/kg per day as first-line therapy [<a href="#rid53">53</a>]. Adjunctive therapies include <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> at an antiplatelet dose of 2 to 5 mg/kg per day or <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>. The dosing and duration of sirolimus treatment are discussed below. (See <a class="local">'Sirolimus plus systemic corticosteroids'</a> below.) </p><p></p><p>Other treatments that have been used alone or in combination for tumors without KMP include <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>, interferon-alpha, and <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> [<a href="#rid27">27,61-65</a>]. However, no single regimen has been studied in comparative prospective trials, and information on long-term outcomes and complete resolution of the tumor is lacking.</p><p class="headingAnchor" id="H357895437"><span class="h2">Patients with Kasabach-Merritt phenomenon</span></p><p class="headingAnchor" id="H701450226"><span class="h3">General considerations</span><span class="headingEndMark"> — </span>Infants with tufted angioma or KHE and associated KMP are at very high risk for complications. Their management primarily involves the treatment of the tumor responsible for the coagulopathy and supportive measures to maintain hemostasis.</p><p>In 2013, an expert panel recommended steroids and <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> as first-line treatment for KHE/KMP [<a href="#rid53">53</a>]. However, subsequent numerous case reports, case series, and a prospective clinical trial have shown very encouraging results with the mammalian (mechanistic) target of rapamycin (mTOR) inhibitor <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, suggesting that it should be considered the preferred first-line therapy [<a href="#rid28">28,63,66-73</a>]. Thus, most clinicians treating KHE with KMP are using sirolimus with or without systemic corticosteroids as first-line treatment, both because it can be orally administered (as opposed to the need for a central line for administration of vincristine) and because the coagulopathy of KMP improves much more rapidly with sirolimus. (See <a class="local">'Sirolimus plus systemic corticosteroids'</a> below.)</p><p class="headingAnchor" id="H2129578666"><span class="h3">First-line therapy</span></p><p class="headingAnchor" id="H3382961175"><span class="h4">Sirolimus plus systemic corticosteroids</span><span class="headingEndMark"> — </span>For large, nonresectable KHE with KMP, we suggest treatment with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> plus systemic corticosteroids as the initial treatment followed by sirolimus as monotherapy. Because sirolimus is an immunosuppressant, we recommend <em>Pneumocystis</em> pneumonia prophylaxis, especially in infants and toddlers (see  <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral corticosteroid dosing</strong> – Oral <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> 2 mg/kg per day is given for two weeks and the weaned over one to two months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sirolimus</strong><strong> dosing </strong>–<strong> </strong><a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> is typically given orally at the dose of 0.8 to 1 mg/m<sup>2</sup> per dose twice daily in children aged 12 months and older, with close pharmacokinetic monitoring [<a href="#rid74">74</a>]. Blood levels of sirolimus should not be higher than 10 to 13 ng/mL. In newborns, lower doses are required with more frequent monitoring (<a class="graphic graphic_table graphicRef115485" href="/z/d/graphic/115485.html" rel="external">table 1</a>) [<a href="#rid75">75,76</a>]. Trough blood levels should be checked weekly, until stable at least twice in a row, and monthly thereafter. Levels should also be monitored with illness. Neonates and infants may need twice-weekly monitoring of trough levels initially. Careful consideration is needed in dosing sirolimus in pediatric patients to achieve the target dose of approximately 10 to 13 ng/mL. Close monitoring of the serum levels should be performed, and dose adjustments should be made accordingly [<a href="#rid75">75,77</a>]. The suggested dosing regimens are derived in part from the phase 2 prospective study (<a class="graphic graphic_table graphicRef115485" href="/z/d/graphic/115485.html" rel="external">table 1</a>) [<a href="#rid28">28</a>]. Neonates and infants need a lower dosing regimen secondary to physiologic differences in drug metabolism [<a href="#rid75">75,77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of treatment</strong> – Multiple reports have noted a rapid response of hematologic parameters within one to three weeks of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> therapy [<a href="#rid28">28,66-68,78</a>]. However, a concern raised in several reports is the phenomenon of "relapse" or worsening of clinical status (increase in the size of the lesion, change in color, pain or, rarely, increase in D-dimer, drop in platelets and/or fibrinogen) after the medication is discontinued or during a "weaning schedule." This can happen relatively quickly even after dramatic clinical response, raising the issue of whether longer-term maintenance therapy with sirolimus may be needed in some cases [<a href="#rid79">79</a>]. </p><p></p><p class="bulletIndent1">Most clinicians will treat high-risk patients for two years and then wean the dose of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> over six months. Patients who "relapse" usually require a lower dose of sirolimus to maintain relief of symptoms.</p><p></p><p class="bulletIndent1">Long-term data on the duration of response to <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, dosing regimens needed during maintenance treatment, and long-term toxicity are limited. Long-term follow-up data of a phase 2 sirolimus study were reported by one of the authors in 2018 [<a href="#rid80">80</a>]. Of 10 patients with KHE and KMP, five were still on small doses of sirolimus five years after the initial year of therapy. No patient had any long-term toxicities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Common adverse effects of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> for infants include mouth sores, abdominal upset, poor oral feeding, immunosuppression, irritability, and the need for modification of vaccination schedules. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting evidence</strong> – Growing evidence from several case series, a phase 2 trial, and a randomized trial supports the efficacy of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> as monotherapy or in combination with oral corticosteroids for KHE with KMP [<a href="#rid28">28,66-69,78,79,81-84</a>], including cases refractory to previous therapy with <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> [<a href="#rid85">85</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a phase 2 clinical trial evaluating the safety and efficacy of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> for the treatment of complicated vascular anomalies (including, but not limited to, KHE) in 61 children, sirolimus induced a partial response (complete response of hematologic parameters with partial tumor response) in all patients with KHE/KMP [<a href="#rid28">28</a>]. Sirolimus was given at the dose of 0.8 mg/m<sup>2</sup> twice daily, with careful monitoring and adjustment to keep serum levels between 10 to 15 ng/mL using pharmacodynamic modeling. Patients also received supportive care, including <em>Pneumocystis </em>pneumonia prophylaxis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A subsequent randomized trial that included 73 patients aged 0 to 14 years with KHE and KMP compared combined therapy with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> plus <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> with sirolimus monotherapy [<a href="#rid78">78</a>]. Patients received sirolimus at a starting dose of 0.8 mg/m<sup>2</sup> twice daily and concurrent prednisolone 2 mg/kg per day or sirolimus alone. Patients who showed stabilization or improvement continued treatment for 12 months and were followed for two years. More patients in the combined therapy group than in the monotherapy group achieved the primary outcome of a durable platelet response at week 4 (95 versus 67 percent, difference 28 percent; 95% CI 10.0-44.7). Complete and nearly complete tumor involution compared with baseline was demonstrated in 81 percent of patients in the combined therapy group versus 58 percent of those in the monotherapy group (difference 23 percent; 95% CI 1.7-41.4). Adverse events occurred with equal frequency in the two groups and included upper respiratory tract infection, mucositis, and nausea/vomiting.</p><p></p><p class="headingAnchor" id="H4012777101"><span class="h3">Second-line therapy</span></p><p class="headingAnchor" id="H1498607927"><span class="h4">Vincristine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">Vincristine</a>, a chemotherapy agent that promotes endothelial apoptosis, was used in the past as a first-line or early second-line therapy in combination with a tapering dose of systemic corticosteroids [<a href="#rid86">86</a>]. However, vincristine has fallen into disfavor, given the longer time to response, need for a central line, and risk of neurotoxicity and other adverse events.</p><p>It can be used as an adjunctive treatment in severe, refractory cases with incomplete response to <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and systemic corticosteroids:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">Vincristine</a> is given at a weekly dose of 0.025 to 0.05 mg/kg for infants &lt;10 kg and 1 to 1.5 mg/m<sup>2 </sup>for infants &gt;10 kg for two months [<a href="#rid53">53,87</a>]. Vincristine is a vesicant and should be given through a central venous line.</p><p></p><p class="bulletIndent1">If a response is noted (hematologic response, complete regression, or reduction in size of the tumor), the administration interval can be increased to every two weeks for two months and then to every three weeks for two months. In one case series, the average time to platelet increase was two months, and the average time to decrease in tumor size was four months [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of treatment</strong> – <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">Vincristine</a> is typically administered for 20 to 24 weeks, based upon the response to treatment and acceptable, therapy-related toxicity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects of <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> include peripheral polyneuropathy, abdominal autonomic dysfunction (constipation), and vocal cord paralysis, and it needs to be given via a central line as it is a vesicant [<a href="#rid86">86,88</a>]. (See  <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Vincristine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting evidence</strong> – Several systematic reviews and meta-analyses of observational studies and one small, randomized trial evaluated the efficacy of <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> for the treatment of KHE with KMP:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a meta-analysis that included 15 studies with 244 patients comparing the efficacy of several treatments, the pooled response rate for <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> was 0.72 (95% CI 0.64-0.79) compared with 0.27 (95% CI 0.17-0.36) for systemic corticosteroids [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another meta-analysis of seven studies (123 patients) published between 2009 and 2017 showed that compared with systemic corticosteroids, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> was more likely to induce hematologic and tumor response (pooled relative risk 2.08, 95% CI 1.38-3.16) [<a href="#rid90">90</a>]. The authors also reviewed 20 additional studies of systemic corticosteroids (15 studies) and vincristine (5 studies), reporting an overall response rate higher for vincristine than for corticosteroids (86 versus 55 percent, respectively). Adverse events were more frequent with corticosteroids than vincristine (52 and 18 percent, respectively).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A multicenter, randomized trial evaluated the efficacy of <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> versus systemic corticosteroids in 59 patients with KHE or tufted angioma, of whom 50 had KMP [<a href="#rid91">91</a>]. Patients received <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 4 mg/kg/day, switched to every other day after a response was noted and then tapered in four to six weeks, or vincristine 0.05 mg/kg weekly four times, then monthly six times, with additional doses added if needed. At one month, more patients in the vincristine group than in the corticosteroid group experienced improvement in thrombocytopenia and tumor texture (80 versus 44 percent and 69 versus 31 percent, respectively). The overall improvement rate (based on percentage change from baseline of a composite score based on platelet count; fibrinogen levels; and tumor size, texture, and appearance) was greater in the vincristine group than in the corticosteroid group (60 versus 34.5 percent, respectively), although the difference was not statistically significant.</p><p></p><p class="bulletIndent1">In a small number of patients, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> has been used in combination with antiplatelet agents [<a href="#rid88">88,92,93</a>]. In a retrospective study, 11 children aged 0 to 36 months were treated with vincristine 0.05 mg/kg weekly for four months [<a href="#rid88">88</a>]. <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> 10 mg/kg per day and <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> 10 mg/kg per day were also given and continued for a total of 14 months. An increase in platelet count to 100,000 or more was observed in all children within three weeks of starting treatment. All patients were alive and clinically free of disease after a median follow-up of 4.5 years (range 2 to 17 years).</p><p></p><p class="headingAnchor" id="H3380810629"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>Antiplatelet agents (eg, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a>) are usually used in combination with other treatments such as systemic corticosteroids and <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> [<a href="#rid88">88</a>]. Aspirin is used in the setting of platelet trapping and consumption to prevent platelet activation and aggregation, a critical pathophysiologic mechanism in the development and perpetuation of KMP [<a href="#rid29">29</a>].</p><p>An antifibrinolytic agent (<a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> or <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">aminocaproic acid</a>) has been used in a few cases of KMP with mixed results [<a href="#rid94">94-97</a>].</p><p><a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a> has been suggested as a possible treatment for tufted angioma and KHE, given its remarkable efficacy in the treatment of infantile hemangiomas. However, in a small case series of 11 patients, improvement was noted only in four patients [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H357895446"><span class="h3">Hemostasis support</span><span class="headingEndMark"> — </span>Although platelet counts in KMP can be alarmingly low (eg, 3000 to 5000/microL), clinicians should not treat "the numbers" but "the patient" [<a href="#rid9">9</a>]. Despite the profound thrombocytopenia, life-threatening hemorrhages are rare. However, severe bleeding can occur in patients with visceral involvement or disseminated intravascular coagulation and in those who have multiorgan failure [<a href="#rid98">98</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet transfusions</strong> – Platelets should <strong>not</strong> be given unless the patient is actively bleeding or in preparation for surgery. In patients undergoing surgical procedures, platelets should be infused during the procedure. The effects of platelet transfusions are very transitory and can actually induce a rapid and, at times, sustained increase in the size of the tumor, probably secondary to increased platelet trapping and clotting within small vessels of the tumor [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cryoprecipitate</strong> – Cryoprecipitate for the correction of hypofibrinogenemia should be given with careful consideration in the following circumstances:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active bleeding</p><p class="bulletIndent2"><span class="glyph">•</span>Before surgical procedures</p><p class="bulletIndent2"><span class="glyph">•</span>Platelet count &lt;10,000/microL </p><p class="bulletIndent2"><span class="glyph">•</span>Fibrinogen &lt;100 mg/dL</p><p class="bulletIndent2"><span class="glyph">•</span>To stabilize the endothelium in critical infants with multiorgan system failure</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coagulation factor replacement</strong> – In case of active bleeding, <a class="drug drug_general" data-topicid="10155" href="/z/d/drug information/10155.html" rel="external">recombinant human factor VIIa</a> can be used at a dose of 90 mcg/kg [<a href="#rid99">99</a>]. (See  <a class="medical medical_review" href="/z/d/html/1341.html" rel="external">"Recombinant factor VIIa: Administration and adverse effects", section on 'Off-label uses'</a>.)</p><p></p><p class="bulletIndent1">Infants with disseminated intravascular coagulation and prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT) may need the replacement of the other coagulation factors with fresh frozen plasma (see  <a class="medical medical_review" href="/z/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children"</a>). Despite abnormal coagulation parameters that sometimes include abnormal PT, aPTT, and international normalized ratio (INR), heparin and low molecular weight heparin should not be used in the management of KMP because it is a unique form of coagulopathy, different from other forms of disseminated intravascular coagulation or localized intravascular coagulopathy, with platelet trapping as its primary inciting event. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Packed red blood cell transfusion</strong> – Transfusion of packed red blood cells should be given if the patient has symptomatic anemia. (See  <a class="medical medical_review" href="/z/d/html/5935.html" rel="external">"Red blood cell transfusion in infants and children: Selection of blood products"</a>.)</p><p></p><p class="headingAnchor" id="H357895453"><span class="h3">Surgical treatment</span><span class="headingEndMark"> — </span>Tufted angiomas and KHE associated with KMP are usually large and infiltrative lesions that do not allow a complete surgical excision. However, for small or localized tumors or tumors whose size has been reduced by pharmacologic therapy, surgical excision is a treatment option [<a href="#rid100">100-102</a>]. Surgical excision may be a second-line approach for tumors that have failed medical management or for imminently life-threatening tumors when the time to response to medical therapy is considered too long [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H1371846"><span class="h3">Embolization</span><span class="headingEndMark"> — </span>In patients with symptomatic or high-risk tumors, embolization may be helpful in decreasing the blood flow to the lesion before initiating a pharmacologic treatment [<a href="#rid103">103-105</a>]. A case series of 34 infants who received transarterial embolization from two to five times each found that the feeding arteries of KHE were numerous, small, and not easily embolized and that platelet increases were either absent or transient [<a href="#rid106">106</a>].</p><p class="headingAnchor" id="H1371853"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>Low-dose radiotherapy is rarely used for the treatment of KMP. Because of the risk of secondary malignancies, radiotherapy should be considered a last resort treatment for tumors that are unresponsive to other therapies [<a href="#rid107">107-112</a>].</p><p class="headingAnchor" id="H357895481"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Tufted angioma and KHE can undergo spontaneous or treatment-induced regression but never resolve completely [<a href="#rid20">20,21</a>]. A study evaluating patients 10 years after their diagnosis found active tumor on radiologic imaging and repeat biopsy in most patients [<a href="#rid37">37</a>].</p><p>In the past, a mortality rate of 12 to 24 percent has been reported among patients with KMP. However, mortality rates have decreased over time due to improved pharmacologic therapy and better supportive care [<a href="#rid24">24</a>]. The leading causes of death include hemorrhage, sepsis, organ failure, or invasion of vital structures. Hemorrhage is more common in retroperitoneal and intrapleural tumors [<a href="#rid36">36,70,107</a>].</p><p>The cutaneous outcome of tufted angioma and KHE includes three types of residual lesions: vascular stains with papules, soft tissue swelling with telangiectasias, and fibrotic subcutaneous infiltrate. Long-term complications that can significantly impair quality of life include lymphedema, recurrent inflammation, pain, and orthopedic issues (eg, contractures, scoliosis, impaired function) [<a href="#rid113">113</a>]. Late complications often arise around puberty [<a href="#rid114">114</a>].</p><p class="headingAnchor" id="H357895488"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Tufted angioma and kaposiform hemangioendothelioma (KHE) are rare, vascular tumors that typically occur during infancy or early childhood. They may be associated with Kasabach-Merritt phenomenon (KMP), a life-threatening complication characterized by severe thrombocytopenia and coagulopathy. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tufted angioma usually presents as infiltrated, firm, dusky red to violaceous plaques or nodules with ill-defined borders (<a class="graphic graphic_picture graphicRef89065" href="/z/d/graphic/89065.html" rel="external">picture 1E</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>KHE<strong> </strong>appears as a subcutaneous mass with a purpuric, bruised appearance (<a class="graphic graphic_picture graphicRef89343" href="/z/d/graphic/89343.html" rel="external">picture 1A</a>). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kasabach-Merritt phenomenon</strong> – KMP is characterized by profound thrombocytopenia and coagulopathy, due to platelet trapping in the tumor and consumption of fibrinogen. The presenting sign is a rapid enlargement of the tumor, which becomes tense, purpuric or ecchymotic, and painful (<a class="graphic graphic_picture graphicRef89100" href="/z/d/graphic/89100.html" rel="external">picture 1C</a>). (See <a class="local">'Kasabach-Merritt phenomenon'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of tufted angioma or KHE is suspected in a child presenting with an atypical, vascular lesion, red to purple in color with ill-defined borders, most often located on the extremities or trunk (<a class="graphic graphic_picture graphicRef89065 graphicRef89100 graphicRef89264 graphicRef89343" href="/z/d/graphic/89065.html" rel="external">picture 1A, 1C-E</a>). A biopsy for histologic and immunohistochemical evaluation may be necessary to confirm the diagnosis.</p><p></p><p class="bulletIndent1">Laboratory findings of severe thrombocytopenia, hypofibrinogenemia, and elevated D-dimer suggest the diagnosis of KMP. (See <a class="local">'Diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of patients without Kasabach-Merritt phenomenon</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Asymptomatic tumors</strong> – For patients without KMP who have small, localized tumors, observation for spontaneous regression may be an option for lesions that are asymptomatic, do not cause functional compromise, and are not disfiguring. Surgical excision, if feasible, is the treatment of choice for patients who desire definitive treatment. (See <a class="local">'Asymptomatic tumors without Kasabach-Merritt phenomenon'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptomatic tumors</strong> – For patients with tumors causing pain or functional impairment, surgical excision, if feasible, is the preferred treatment. However, as complete resection cannot be performed in many cases, medical therapy is needed before attempting surgery: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For tufted angiomas, we suggest <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 5 mg/kg per day (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For KHE, we suggest oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> 2 mg/kg per day as first-line therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> 2 to 5 mg/kg per day and <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> can be given as adjunctive therapies. (See <a class="local">'Patients without Kasabach-Merritt phenomenon'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of patients with Kasabach-Merritt phenomenon</strong> – For large, nonresectable tumors with KMP, we recommend initial treatment with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and systemic corticosteroids (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>) (see <a class="local">'Patients with Kasabach-Merritt phenomenon'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> is typically given at the dose of 0.8 mg/m<sup>2</sup> per dose with close monitoring of blood levels and supportive care. Neonates and infants may need a lower dosing regimen due to physiologic differences in drug metabolism (<a class="graphic graphic_table graphicRef115485" href="/z/d/graphic/115485.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> 2 mg/kg/day is given for <strong>two weeks</strong> and then weaned over a two- to four-week period.</p><p></p><p class="bulletIndent1"><em>Pneumocystis</em> pneumonia prophylaxis must be given to infants and toddlers. (See  <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemostasis support</strong> – The need for hemostasis support, in particular platelet transfusion and fibrinogen replacement, should be based upon careful evaluation of the acuteness of the clinical presentation and the patient's needs (eg, active bleeding, upcoming surgery). (See <a class="local">'Hemostasis support'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cho KH, Kim SH, Park KC, et al. Angioblastoma (Nakagawa)--is it the same as tufted angioma? Clin Exp Dermatol 1991; 16:110.</a></li><li><a class="nounderline abstract_t">Jones EW, Orkin M. Tufted angioma (angioblastoma). A benign progressive angioma, not to be confused with Kaposi's sarcoma or low-grade angiosarcoma. J Am Acad Dermatol 1989; 20:214.</a></li><li><a class="nounderline abstract_t">Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr 2013; 162:142.</a></li><li><a class="nounderline abstract_t">Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis. Am J Surg Pathol 1993; 17:321.</a></li><li><a class="nounderline abstract_t">Arai E, Kuramochi A, Tsuchida T, et al. Usefulness of D2-40 immunohistochemistry for differentiation between kaposiform hemangioendothelioma and tufted angioma. J Cutan Pathol 2006; 33:492.</a></li><li><a class="nounderline abstract_t">Chu CY, Hsiao CH, Chiu HC. Transformation between Kaposiform hemangioendothelioma and tufted angioma. Dermatology 2003; 206:334.</a></li><li><a class="nounderline abstract_t">Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr 1997; 130:631.</a></li><li><a class="nounderline abstract_t">Rodriguez V, Lee A, Witman PM, Anderson PA. Kasabach-merritt phenomenon: case series and retrospective review of the mayo clinic experience. J Pediatr Hematol Oncol 2009; 31:522.</a></li><li><a class="nounderline abstract_t">Ryan C, Price V, John P, et al. Kasabach-Merritt phenomenon: a single centre experience. Eur J Haematol 2010; 84:97.</a></li><li><a class="nounderline abstract_t">Lee B, Chiu M, Soriano T, Craft N. Adult-onset tufted angioma: a case report and review of the literature. Cutis 2006; 78:341.</a></li><li><a class="nounderline abstract_t">Kelly M. Kasabach-Merritt phenomenon. Pediatr Clin North Am 2010; 57:1085.</a></li><li><a class="nounderline abstract_t">Lyons LL, North PE, Mac-Moune Lai F, et al. Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol 2004; 28:559.</a></li><li><a class="nounderline abstract_t">Debelenko LV, Perez-Atayde AR, Mulliken JB, et al. D2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendothelioma. Mod Pathol 2005; 18:1454.</a></li><li><a class="nounderline abstract_t">Folpe AL, Veikkola T, Valtola R, Weiss SW. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol 2000; 13:180.</a></li><li><a class="nounderline abstract_t">Lim YH, Bacchiocchi A, Qiu J, et al. GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation. Am J Hum Genet 2016; 99:443.</a></li><li><a class="nounderline abstract_t">Feito-Rodríguez M, Sánchez-Orta A, De Lucas R, et al. Congenital tufted angioma: A multicenter retrospective study of 30 cases. Pediatr Dermatol 2018; 35:808.</a></li><li><a class="nounderline abstract_t">Herron MD, Coffin CM, Vanderhooft SL. Tufted angiomas: variability of the clinical morphology. Pediatr Dermatol 2002; 19:394.</a></li><li><a class="nounderline abstract_t">McAleer MA, Kirby B, Sheahan K, Collins P. An erythematous patch and plaque on the shoulder--quiz case. Acquired tufted angioma (TA). Arch Dermatol 2008; 144:1217.</a></li><li><a class="nounderline abstract_t">Fujita H, Asahina A, Tamaki K. Extensive tufted angioma of the left arm in a 47-year-old woman. Clin Exp Dermatol 2009; 34:e216.</a></li><li><a class="nounderline abstract_t">Lam WY, Mac-Moune Lai F, Look CN, et al. Tufted angioma with complete regression. J Cutan Pathol 1994; 21:461.</a></li><li><a class="nounderline abstract_t">Miyamoto T, Mihara M, Mishima E, et al. Acquired tufted angioma showing spontaneous regression. Br J Dermatol 1992; 127:645.</a></li><li><a class="nounderline abstract_t">Wang L, Liu L, Wang G, Gao T. Congenital disseminated tufted angioma. J Cutan Pathol 2013; 40:405.</a></li><li><a class="nounderline abstract_t">Al-Za'abi AM, Ghazarian D, Greenberg GR, Shaw JC. Eruptive tufted angiomas in a patient with Crohn's disease. J Clin Pathol 2005; 58:214.</a></li><li><a class="nounderline abstract_t">Mulliken JB, Anupindi S, Ezekowitz RA, Mihm MC Jr. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 13-2004. A newborn girl with a large cutaneous lesion, thrombocytopenia, and anemia. N Engl J Med 2004; 350:1764.</a></li><li><a class="nounderline abstract_t">Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997; 100:1377.</a></li><li><a class="nounderline abstract_t">Kuo C, Warren M, Malvar J, et al. Kaposiform hemangioendothelioma of the bone in children and adolescents. Pediatr Blood Cancer 2022; 69:e29392.</a></li><li><a class="nounderline abstract_t">Gruman A, Liang MG, Mulliken JB, et al. Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon. J Am Acad Dermatol 2005; 52:616.</a></li><li><a class="nounderline abstract_t">Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics 2016; 137:e20153257.</a></li><li><a class="nounderline abstract_t">O'Rafferty C, O'Regan GM, Irvine AD, Smith OP. Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon. Br J Haematol 2015; 171:38.</a></li><li><a class="nounderline abstract_t">Hu PA, Zhou ZR. Clinical and imaging features of Kaposiform Hemangioendothelioma. Br J Radiol 2018; 91:20170798.</a></li><li><a class="nounderline abstract_t">Ryu YJ, Choi YH, Cheon JE, et al. Imaging findings of Kaposiform Hemangioendothelioma in children. Eur J Radiol 2017; 86:198.</a></li><li><a class="nounderline abstract_t">Gong X, Ying H, Zhang Z, et al. Ultrasonography and magnetic resonance imaging features of kaposiform hemangioendothelioma and tufted angioma. J Dermatol 2019; 46:835.</a></li><li><a class="nounderline abstract_t">Peng S, Xia C, Yang K, et al. Kaposiform haemangioendothelioma: magnetic resonance imaging features in 64 cases. BMC Pediatr 2021; 21:107.</a></li><li><a class="nounderline abstract_t">Kim HW, Yoo SY, Oh S, et al. Ultrasonography of Pediatric Superficial Soft Tissue Tumors and Tumor-Like Lesions. Korean J Radiol 2020; 21:341.</a></li><li><a class="nounderline abstract_t">Enjolras O, Soupre V, Picard A. Uncommon benign infantile vascular tumors. Adv Dermatol 2008; 24:105.</a></li><li><a class="nounderline abstract_t">Brasanac D, Janic D, Boricic I, et al. Retroperitoneal kaposiform hemangioendothelioma with tufted angioma-like features in an infant with Kasabach-Merritt syndrome. Pathol Int 2003; 53:627.</a></li><li><a class="nounderline abstract_t">Enjolras O, Mulliken JB, Wassef M, et al. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol 2000; 42:225.</a></li><li><a class="nounderline abstract_t">Croteau SE, Kozakewich HP, Perez-Atayde AR, et al. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly. J Pediatr 2014; 164:383.</a></li><li><a class="nounderline abstract_t">Ji Y, Chen S, Peng S, et al. Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences. Orphanet J Rare Dis 2019; 14:165.</a></li><li><a class="nounderline abstract_t">Barclay SF, Inman KW, Luks VL, et al. A somatic activating NRAS variant associated with kaposiform lymphangiomatosis. Genet Med 2019; 21:1517.</a></li><li><a class="nounderline abstract_t">Safi F, Gupta A, Adams D, et al. Kaposiform lymphangiomatosis, a newly characterized vascular anomaly presenting with hemoptysis in an adult woman. Ann Am Thorac Soc 2014; 11:92.</a></li><li><a class="nounderline abstract_t">Fernandes VM, Fargo JH, Saini S, et al. Kaposiform lymphangiomatosis: unifying features of a heterogeneous disorder. Pediatr Blood Cancer 2015; 62:901.</a></li><li><a class="nounderline abstract_t">Wang Z, Li K, Yao W, et al. Successful treatment of kaposiform lymphangiomatosis with sirolimus. Pediatr Blood Cancer 2015; 62:1291.</a></li><li><a class="nounderline abstract_t">Gengler C, Guillou L. Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology 2006; 48:63.</a></li><li><a class="nounderline abstract_t">Variend S, Bax NM, van Gorp J. Are infantile myofibromatosis, congenital fibrosarcoma and congenital haemangiopericytoma histogenetically related? Histopathology 1995; 26:57.</a></li><li><a class="nounderline abstract_t">Mentzel T, Calonje E, Nascimento AG, Fletcher CD. Infantile hemangiopericytoma versus infantile myofibromatosis. Study of a series suggesting a continuous spectrum of infantile myofibroblastic lesions. Am J Surg Pathol 1994; 18:922.</a></li><li><a class="nounderline abstract_t">Fernandez-Pineda I, Parida L, Jenkins JJ, et al. Childhood hemangiopericytoma: review of St Jude Children's Research Hospital. J Pediatr Hematol Oncol 2011; 33:356.</a></li><li><a class="nounderline abstract_t">Frieden IJ, Rogers M, Garzon MC. Conditions masquerading as infantile haemangioma: Part 2. Australas J Dermatol 2009; 50:153.</a></li><li><a class="nounderline abstract_t">Frieden IJ, Rogers M, Garzon MC. Conditions masquerading as infantile haemangioma: Part 1. Australas J Dermatol 2009; 50:77.</a></li><li><a class="nounderline abstract_t">Grassia KL, Peterman CM, Iacobas I, et al. Clinical case series of pediatric hepatic angiosarcoma. Pediatr Blood Cancer 2017; 64.</a></li><li><a class="nounderline abstract_t">Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med 1995; 332:1181.</a></li><li><a class="nounderline abstract_t">Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865.</a></li><li><a class="nounderline abstract_t">Drolet BA, Trenor CC 3rd, Brandão LR, et al. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr 2013; 163:285.</a></li><li><a class="nounderline abstract_t">Browning J, Frieden I, Baselga E, et al. Congenital, self-regressing tufted angioma. Arch Dermatol 2006; 142:749.</a></li><li><a class="nounderline abstract_t">Ishikawa K, Hatano Y, Ichikawa H, et al. The spontaneous regression of tufted angioma. A case of regression after two recurrences and a review of 27 cases reported in the literature. Dermatology 2005; 210:346.</a></li><li><a class="nounderline abstract_t">Osio A, Fraitag S, Hadj-Rabia S, et al. Clinical spectrum of tufted angiomas in childhood: a report of 13 cases and a review of the literature. Arch Dermatol 2010; 146:758.</a></li><li><a class="nounderline abstract_t">Escudero-Góngora MM, Corral-Magaña O, Gómez C, Martín-Santiago A. Topical Rapamycin: An Additional Therapeutic Option for Tufted Angioma in Adults. Actas Dermosifiliogr (Engl Ed) 2018; 109:192.</a></li><li><a class="nounderline abstract_t">Burleigh A, Kanigsberg N, Lam JM. Topical rapamycin (sirolimus) for the treatment of uncomplicated tufted angiomas in two children and review of the literature. Pediatr Dermatol 2018; 35:e286.</a></li><li><a class="nounderline abstract_t">Zhang X, Yang K, Chen S, Ji Y. Tacrolimus ointment for the treatment of superficial kaposiform hemangioendothelioma and tufted angioma. J Dermatol 2019; 46:898.</a></li><li><a class="nounderline abstract_t">Xiao Y, Hao D, Li Y, et al. Topical tacrolimus reduces the severe pain of tufted angioma: Case report. Dermatol Ther 2020; 33:e14412.</a></li><li><a class="nounderline abstract_t">Javvaji S, Frieden IJ. Response of tufted angiomas to low-dose aspirin. Pediatr Dermatol 2013; 30:124.</a></li><li><a class="nounderline abstract_t">Munn SE, Jackson JE, Jones RR. Tufted haemangioma responding to high-dose systemic steroids: a case report and review of the literature. Clin Exp Dermatol 1994; 19:511.</a></li><li><a class="nounderline abstract_t">Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57:1018.</a></li><li><a class="nounderline abstract_t">Chiu YE, Drolet BA, Blei F, et al. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2012; 59:934.</a></li><li><a class="nounderline abstract_t">Wang Z, Li K, Dong K, et al. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2014; 61:1518.</a></li><li><a class="nounderline abstract_t">Blatt J, Stavas J, Moats-Staats B, et al. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer 2010; 55:1396.</a></li><li><a class="nounderline abstract_t">Wang Z, Li K, Dong K, et al. Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus. J Pediatr Hematol Oncol 2015; 37:72.</a></li><li><a class="nounderline abstract_t">Jahnel J, Lackner H, Reiterer F, et al. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus. Klin Padiatr 2012; 224:395.</a></li><li><a class="nounderline abstract_t">Lackner H, Karastaneva A, Schwinger W, et al. Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr 2015; 174:1579.</a></li><li><a class="nounderline abstract_t">Uno T, Ito S, Nakazawa A, et al. Successful treatment of Kaposiform hemangioendothelioma with everolimus. Pediatr Blood Cancer 2015; 62:536.</a></li><li><a class="nounderline abstract_t">Kai L, Wang Z, Yao W, et al. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma. J Cancer Res Clin Oncol 2014; 140:471.</a></li><li><a class="nounderline abstract_t">Carrington PR. Truncal location of hemangioendotheliomas may indicate potentially more serious involvement with resulting Kasabach-Merritt syndrome than size determinant alone. J Am Acad Dermatol 2006; 54:922.</a></li><li><a class="nounderline abstract_t">Iacobas I, Simon ML, Amir T, et al. Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms. Clin Imaging 2015; 39:529.</a></li><li><a class="nounderline abstract_t">Mariani LG, Schmitt IR, Garcia CD, Kiszewski AE. Low dose sirolimus treatment for refractory tufted angioma and congenital kaposiform hemangioendothelioma, both with Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2019; 66:e27810.</a></li><li><a class="nounderline abstract_t">Mizuno T, Emoto C, Fukuda T, et al. Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. Eur J Pharm Sci 2017; 109S:S124.</a></li><li><a class="nounderline abstract_t">Castello MA, Ragni G, Antimi A, et al. Successful management with interferon alpha-2a after prednisone therapy failure in an infant with a giant cavernous hemangioma. Med Pediatr Oncol 1997; 28:213.</a></li><li><a class="nounderline abstract_t">Mizuno T, Fukuda T, Emoto C, et al. Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. Pediatr Blood Cancer 2017; 64.</a></li><li><a class="nounderline abstract_t">Ji Y, Chen S, Zhou J, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial. Blood 2022; 139:1619.</a></li><li><a class="nounderline abstract_t">Tasani M, Ancliff P, Glover M. Sirolimus therapy for children with problematic kaposiform haemangioendothelioma and tufted angioma. Br J Dermatol 2017; 177:e344.</a></li><li class="breakAll">Adams D, Trenor C, Ricci K, et al. Phase II Study of Sirolimus and Complicated Vascular Anomalies: Long term outcomes in Kaposiform Hemangioendothelioma. 22nd International Workshop of the International Society for the Study of Vascular Anomalies, Amsterdam, the Netherlands, June 2018.</li><li><a class="nounderline abstract_t">Nadal M, Giraudeau B, Tavernier E, et al. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review. Acta Derm Venereol 2016; 96:448.</a></li><li><a class="nounderline abstract_t">Boccara O, Puzenat E, Proust S, et al. The effects of sirolimus on Kasabach-Merritt phenomenon coagulopathy. Br J Dermatol 2018; 178:e114.</a></li><li><a class="nounderline abstract_t">Ji Y, Chen S, Xiang B, et al. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study. Int J Cancer 2017; 141:848.</a></li><li><a class="nounderline abstract_t">Maza-Morales M, Valdés-Loperena S, Durán-McKinster LC, García-Romero MT. The use of mTOR inhibitors for the treatment of kaposiform hemangioendothelioma. A systematic review. Pediatr Dermatol 2023; 40:440.</a></li><li><a class="nounderline abstract_t">Wang H, Duan Y, Gao Y, Guo X. Sirolimus for Vincristine-Resistant Kasabach-Merritt Phenomenon: Report of Eight Patients. Pediatr Dermatol 2017; 34:261.</a></li><li><a class="nounderline abstract_t">Haisley-Royster C, Enjolras O, Frieden IJ, et al. Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 2002; 24:459.</a></li><li><a class="nounderline abstract_t">Wang Z, Li K, Yao W, et al. Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up. Pediatr Blood Cancer 2015; 62:577.</a></li><li><a class="nounderline abstract_t">Fernandez-Pineda I, Lopez-Gutierrez JC, Chocarro G, et al. Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2013; 60:1478.</a></li><li><a class="nounderline abstract_t">Liu XH, Li JY, Qu XH, et al. Treatment of kaposiform hemangioendothelioma and tufted angioma. Int J Cancer 2016; 139:1658.</a></li><li><a class="nounderline abstract_t">Yao W, Li K, Wang Z, et al. Comparison of Corticosteroid and Vincristine in Treating Kaposiform Hemangioendothelioma and Tufted Angioma: A Systematic Review and Meta-Analysis. Eur J Pediatr Surg 2019; 29:401.</a></li><li><a class="nounderline abstract_t">Yao W, Li K, Wang Z, et al. Comparison of efficacy and safety of corticosteroid and vincristine in treating kaposiform hemangioendothelioma and tufted angioma: A multicenter prospective randomized controlled clinical trial. J Dermatol 2021; 48:576.</a></li><li><a class="nounderline abstract_t">Barabash-Neila R, García-Rodríguez E, Bernabeu-Wittel J, et al. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with vincristine and ticlopidine. Indian J Pediatr 2012; 79:1386.</a></li><li><a class="nounderline abstract_t">López V, Martí N, Pereda C, et al. Successful management of Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using vincristine and ticlopidine. Pediatr Dermatol 2009; 26:365.</a></li><li><a class="nounderline abstract_t">Dresse MF, David M, Hume H, et al. Successful treatment of Kasabach-Merritt syndrome with prednisone and epsilon-aminocaproic acid. Pediatr Hematol Oncol 1991; 8:329.</a></li><li><a class="nounderline abstract_t">Hanna BD, Bernstein M. Tranexamic acid in the treatment of Kasabach-Merritt syndrome in infants. Am J Pediatr Hematol Oncol 1989; 11:191.</a></li><li><a class="nounderline abstract_t">Ortel TL, Onorato JJ, Bedrosian CL, Kaufman RE. Antifibrinolytic therapy in the management of the Kasabach Merritt syndrome. Am J Hematol 1988; 29:44.</a></li><li><a class="nounderline abstract_t">Shulkin BL, Argenta LC, Cho KJ, Castle VP. Kasabach-Merritt syndrome: treatment with epsilon-aminocaproic acid and assessment by indium 111 platelet scintigraphy. J Pediatr 1990; 117:746.</a></li><li><a class="nounderline abstract_t">San Miguel FL, Spurbeck W, Budding C, Horton J. Kaposiform hemangioendothelioma: a rare cause of spontaneous hemothorax in infancy. Review of the literature. J Pediatr Surg 2008; 43:e37.</a></li><li><a class="nounderline abstract_t">Janic D, Brasanac D, Krstovski N, et al. The use of recombinant activated factor VII during major surgery in a child with Kasabach-Merritt syndrome. Paediatr Anaesth 2009; 19:177.</a></li><li><a class="nounderline abstract_t">Abass K, Saad H, Kherala M, Abd-Elsayed AA. Successful treatment of kasabach-merritt syndrome with vincristine and surgery: a case report and review of literature. Cases J 2008; 1:9.</a></li><li><a class="nounderline abstract_t">Drolet BA, Scott LA, Esterly NB, Gosain AK. Early surgical intervention in a patient with Kasabach-Merritt phenomenon. J Pediatr 2001; 138:756.</a></li><li><a class="nounderline abstract_t">Jiang RS, Hu R. Successful treatment of Kasabach-Merritt syndrome arising from kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery. Int J Clin Oncol 2012; 17:512.</a></li><li><a class="nounderline abstract_t">Garcia-Monaco R, Giachetti A, Peralta O, et al. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with embolization and vincristine in two newborns. J Vasc Interv Radiol 2012; 23:417.</a></li><li><a class="nounderline abstract_t">Hosono S, Ohno T, Kimoto H, et al. Successful transcutaneous arterial embolization of a giant hemangioma associated with high-output cardiac failure and Kasabach-Merritt syndrome in a neonate: a case report. J Perinat Med 1999; 27:399.</a></li><li><a class="nounderline abstract_t">Zhou SY, Li HB, Mao YM, et al. Successful treatment of Kasabach-Merritt syndrome with transarterial embolization and corticosteroids. J Pediatr Surg 2013; 48:673.</a></li><li><a class="nounderline abstract_t">Tan X, Liu Z, Zhou S, et al. Analysis of angiographic characteristics of kaposiform hemangioendothelioma and investigation of the value of transcatheter arterial embolization therapy. Transl Pediatr 2021; 10:3194.</a></li><li><a class="nounderline abstract_t">Atahan IL, Cengiz M, Ozyar E, Gürkaynak M. Radiotherapy in the management of Kasabach-Merritt syndrome: a case report. Pediatr Hematol Oncol 2001; 18:471.</a></li><li><a class="nounderline abstract_t">Hesselmann S, Micke O, Marquardt T, et al. Case report: Kasabach-Merritt syndrome: a review of the therapeutic options and a case report of successful treatment with radiotherapy and interferon alpha. Br J Radiol 2002; 75:180.</a></li><li><a class="nounderline abstract_t">Kwok-Williams M, Perez Z, Squire R, et al. Radiotherapy for life-threatening mediastinal hemangioma with Kasabach-Merritt syndrome. Pediatr Blood Cancer 2007; 49:739.</a></li><li><a class="nounderline abstract_t">Leong E, Bydder S. Use of radiotherapy to treat life-threatening Kasabach-Merritt syndrome. J Med Imaging Radiat Oncol 2009; 53:87.</a></li><li><a class="nounderline abstract_t">Mitsuhashi N, Furuta M, Sakurai H, et al. Outcome of radiation therapy for patients with Kasabach-Merritt syndrome. Int J Radiat Oncol Biol Phys 1997; 39:467.</a></li><li><a class="nounderline abstract_t">Malhotra Y, Yang CS, McNamara J, Antaya RJ. Congenital kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon successfully treated with low-dose radiation therapy. Pediatr Dermatol 2014; 31:595.</a></li><li><a class="nounderline abstract_t">Boccara O, Fraitag S, Lasne D, et al. Kaposiform Haemangioendothelioma-spectrum Lesions with Kasabach-Merritt Phenomenon: Retrospective Analysis and Long-term Outcome. Acta Derm Venereol 2016; 96:77.</a></li><li><a class="nounderline abstract_t">Schaefer BA, Wang D, Merrow AC, et al. Long-term outcome for kaposiform hemangioendothelioma: A report of two cases. Pediatr Blood Cancer 2017; 64:284.</a></li></ol></div><div id="topicVersionRevision">Topic 86314 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2032370" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Angioblastoma (Nakagawa)--is it the same as tufted angioma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2644316" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tufted angioma (angioblastoma). A benign progressive angioma, not to be confused with Kaposi's sarcoma or low-grade angiosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22871490" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8494101" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16872472" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Usefulness of D2-40 immunohistochemistry for differentiation between kaposiform hemangioendothelioma and tufted angioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12771476" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Transformation between Kaposiform hemangioendothelioma and tufted angioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9108863" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19564750" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Kasabach-merritt phenomenon: case series and retrospective review of the mayo clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889011" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Kasabach-Merritt phenomenon: a single centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17186794" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Adult-onset tufted angioma: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20888459" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Kasabach-Merritt phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15105642" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15920541" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : D2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10697276" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27476652" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30318642" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Congenital tufted angioma: A multicenter retrospective study of 30 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12383094" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tufted angiomas: variability of the clinical morphology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794471" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : An erythematous patch and plaque on the shoulder--quiz case. Acquired tufted angioma (TA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19323667" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Extensive tufted angioma of the left arm in a 47-year-old woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7868759" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Tufted angioma with complete regression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1476925" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acquired tufted angioma showing spontaneous regression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23373432" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Congenital disseminated tufted angioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15677546" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Eruptive tufted angiomas in a patient with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15103004" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 13-2004. A newborn girl with a large cutaneous lesion, thrombocytopenia, and anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9385948" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34606171" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Kaposiform hemangioendothelioma of the bone in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15793511" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26783326" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26123689" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29536769" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical and imaging features of Kaposiform Hemangioendothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28027747" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Imaging findings of Kaposiform Hemangioendothelioma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31373042" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Ultrasonography and magnetic resonance imaging features of kaposiform hemangioendothelioma and tufted angioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33657997" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Kaposiform haemangioendothelioma: magnetic resonance imaging features in 64 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32090527" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ultrasonography of Pediatric Superficial Soft Tissue Tumors and Tumor-Like Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19263597" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Uncommon benign infantile vascular tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14507321" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Retroperitoneal kaposiform hemangioendothelioma with tufted angioma-like features in an infant with Kasabach-Merritt syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10642677" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Residual lesions after Kasabach-Merritt phenomenon in 41 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24252784" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31277673" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30542204" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24460439" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Kaposiform lymphangiomatosis, a newly characterized vascular anomaly presenting with hemoptysis in an adult woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25307772" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Kaposiform lymphangiomatosis: unifying features of a heterogeneous disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25598153" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Successful treatment of kaposiform lymphangiomatosis with sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16359538" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Solitary fibrous tumour and haemangiopericytoma: evolution of a concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7713484" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Are infantile myofibromatosis, congenital fibrosarcoma and congenital haemangiopericytoma histogenetically related?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8067513" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Infantile hemangiopericytoma versus infantile myofibromatosis. Study of a series suggesting a continuous spectrum of infantile myofibroblastic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21602721" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Childhood hemangiopericytoma: review of St Jude Children's Research Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19659975" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Conditions masquerading as infantile haemangioma: Part 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19397559" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Conditions masquerading as infantile haemangioma: Part 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28521077" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical case series of pediatric hepatic angiosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7700310" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7997879" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23796341" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16785378" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Congenital, self-regressing tufted angioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15942226" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The spontaneous regression of tufted angioma. A case of regression after two recurrences and a review of 27 cases reported in the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20644037" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical spectrum of tufted angiomas in childhood: a report of 13 cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28811001" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Topical Rapamycin: An Additional Therapeutic Option for Tufted Angioma in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30015406" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Topical rapamycin (sirolimus) for the treatment of uncomplicated tufted angiomas in two children and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31373046" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Tacrolimus ointment for the treatment of superficial kaposiform hemangioendothelioma and tufted angioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33063910" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Topical tacrolimus reduces the severe pain of tufted angioma: Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22429045" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Response of tufted angiomas to low-dose aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7889677" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Tufted haemangioma responding to high-dose systemic steroids: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21445948" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sirolimus for the treatment of complicated vascular anomalies in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22648868" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24482015" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20730884" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Treatment of childhood kaposiform hemangioendothelioma with sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24309604" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070861" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26040705" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Sirolimus for the treatment of children with various complicated vascular anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25306933" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Successful treatment of Kaposiform hemangioendothelioma with everolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24464150" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16635691" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Truncal location of hemangioendotheliomas may indicate potentially more serious involvement with resulting Kasabach-Merritt syndrome than size determinant alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25662209" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31087627" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Low dose sirolimus treatment for refractory tufted angioma and congenital kaposiform hemangioendothelioma, both with Kasabach-Merritt phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28526601" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024520" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Successful management with interferon alpha-2a after prednisone therapy failure in an infant with a giant cavernous hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28205374" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35030255" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28485019" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Sirolimus therapy for children with problematic kaposiform haemangioendothelioma and tufted angioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28485019" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sirolimus therapy for children with problematic kaposiform haemangioendothelioma and tufted angioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26607948" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28796887" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The effects of sirolimus on Kasabach-Merritt phenomenon coagulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28486787" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36716766" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The use of mTOR inhibitors for the treatment of kaposiform hemangioendothelioma. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28198567" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Sirolimus for Vincristine-Resistant Kasabach-Merritt Phenomenon: Report of Eight Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12218593" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25346262" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23609996" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27252149" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Treatment of kaposiform hemangioendothelioma and tufted angioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30372769" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Comparison of Corticosteroid and Vincristine in Treating Kaposiform Hemangioendothelioma and Tufted Angioma: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33608936" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Comparison of efficacy and safety of corticosteroid and vincristine in treating kaposiform hemangioendothelioma and tufted angioma: A multicenter prospective randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161581" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with vincristine and ticlopidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706115" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Successful management of Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using vincristine and ticlopidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1669958" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Successful treatment of Kasabach-Merritt syndrome with prednisone and epsilon-aminocaproic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2751074" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Tranexamic acid in the treatment of Kasabach-Merritt syndrome in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3177369" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Antifibrinolytic therapy in the management of the Kasabach Merritt syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2231207" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Kasabach-Merritt syndrome: treatment with epsilon-aminocaproic acid and assessment by indium 111 platelet scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18206444" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Kaposiform hemangioendothelioma: a rare cause of spontaneous hemothorax in infancy. Review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207911" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The use of recombinant activated factor VII during major surgery in a child with Kasabach-Merritt syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18577262" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Successful treatment of kasabach-merritt syndrome with vincristine and surgery: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11343057" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Early surgical intervention in a patient with Kasabach-Merritt phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947597" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Successful treatment of Kasabach-Merritt syndrome arising from kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22365299" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with embolization and vincristine in two newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10642962" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Successful transcutaneous arterial embolization of a giant hemangioma associated with high-output cardiac failure and Kasabach-Merritt syndrome in a neonate: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23480932" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Successful treatment of Kasabach-Merritt syndrome with transarterial embolization and corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35070833" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Analysis of angiographic characteristics of kaposiform hemangioendothelioma and investigation of the value of transcatheter arterial embolization therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11594711" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Radiotherapy in the management of Kasabach-Merritt syndrome: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11893644" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Case report: Kasabach-Merritt syndrome: a review of the therapeutic options and a case report of successful treatment with radiotherapy and interferon alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16453298" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Radiotherapy for life-threatening mediastinal hemangioma with Kasabach-Merritt syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453533" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Use of radiotherapy to treat life-threatening Kasabach-Merritt syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9308952" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Outcome of radiation therapy for patients with Kasabach-Merritt syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23458157" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Congenital kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon successfully treated with low-dose radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26084625" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Kaposiform Haemangioendothelioma-spectrum Lesions with Kasabach-Merritt Phenomenon: Retrospective Analysis and Long-term Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27701822" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Long-term outcome for kaposiform hemangioendothelioma: A report of two cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
